Questions discussed in this category
In FRAIL-AF, participants were switched from VKA to dabigatran, rivaroxaban, apixaban, and edoxaban.
Individual times in the therapeutic range while on VKA treatment was not registered in FRAIL-AF.
In the span between the HACA trial and the Targeted Temperature Management in Out-of-Hospital Cardiac Arrest study (Dankiewicz et al., PMID 34133859),...
In FRAIL-AF, switching VKA therapy to a NOAC was associated with higher risk of bleeding in elderly, frail patients.
23862176932286017673163431789217692
Papers discussed in this category
The New England journal of medicine, 2002-02-21
N Engl J Med, 2013 Nov 17
Cureus, 2022 Sep 11
Crit Care, 2020 Jan 06
Circulation, 2023 Aug 27
JAMA, 2022 May 17
JAMA, 2013 May 22
The New England journal of medicine, 2013-06-20
The New England journal of medicine, 2016 Jun 08
The New England journal of medicine, 2024 May 16
Lancet (London, England), 2023 May 25